my personal edition > epilepsy > news


  E-Mail this DGNews to a colleague

DGNews

Keppra (Levetiracetam) Offers Sustained Efficacy, Reduction In Seizure Frequency

LONDON, ENGLAND -- February 7, 2003 -- New long-term data published in an international medical journal - Epilepsy Research - show that Keppra (levetiracetam) offers sustained efficacy, as add-on, over the longer term - up to 54 months (4.5 years) - in reducing seizure frequency in adult patients with difficult to treat partial seizures. In addition, the data reveal that long-term treatment Keppra remains very well tolerated by the patients.

These data further demonstrate the favourable efficacy and safety profile of Keppra (levetiracetam), confirming its place at the forefront of the management of epilepsy. Keppra is currently indicated as adjunctive treatment of partial onset seizures, with or without secondary generalisation, in adults with epilepsy.

To our knowledge, this is the first and largest ever published study to collate data on patient retention and seizure freedom rates for adults with refractory epilepsy over a long-term (up to 54-month) treatment period. Data from 1,422 patients were analysed for changes in seizure frequency per week, seizure freedom and adverse events.

The lead investigator on this new study is Professor Elinor Ben-Menachem, from the Department of Clinical Neuroscience, Sahlgren University Hospital, Göteborg, Sweden. Commenting on the data, Professor Ben-Menachem said, "For the first time, long-term Keppra data from patients cohorts are available showing that treatment with Keppra gives effective, sustained antiepileptic benefits by reducing seizure frequency, as well as achieving the optimal treatment goal - seizure freedom. Our research shows that, with levetiracetam (Keppra), efficacy is sustained over long periods. This is good news for physicians, who can confidently choose Keppra to treat their patients in the long-term."

Significant reduction in seizure frequency

In this analysis, the median percentage reduction in seizure frequency from baseline did not decrease over time within each cohort (the sub-groups of patients) exposed to Keppra for varying periods of time. This suggests that tolerance with Keppra did not occur.

It is of importance to mention that patients included in the study suffered from a very refractory epilepsy, with a median seizure frequency per week of 2.17. The analysis revealed that overall, 38.6% and 20.1% of patients experienced a decrease in the numbers of seizures by at least 50% and 75% respectively. In addition, 4.6% of the 1,422 patients were completely seizure free from the first day of treatment until their last day, with the median duration of seizure freedom at 385 days. 11.7% of patients were seizure-free during the last 6 months of follow up, and 8.9% were seizure-free during the last 12 months. These data further confirm the strong efficacy of Keppra in the management of epilepsy.

Reduction in concomitant medication

The analysis also revealed that there was a tendency towards a reduction in the number of additional AEDs taken by patients; 14.4% of patients took a fewer number of AEDs at the end of the treatment compared to the start, and 5.5% of patients were only treated with Keppra at the end. The incidence of adverse events reported in this trial is very similar to the incidence described in previous clinical studies, confirming the safety and tolerability profile for KEPPRA.

"Seizure control, reduction and elimination are the key concerns for epileptologists and neurologists. Those new data show that levetiracetam could help doctors and patients achieve these goals. Levetiracetam represents a strong treatment option for many patients with epilepsy," commented Professor Ben-Menachem.

Keppra received approval by the FDA (U.S. Food and Drug Administration) in November 1999 and by the European Commission in September 2000. It is estimated that 50 million people world-wide have epilepsy2.

Keppra spokesperson Dr Peter Verdru, UCB Global Medical Manager, CNS said, "These long-term seizure freedom results have convinced us to continue our commitment to investing in clinical research that may lead to the improvement of the quality of life of people with epilepsy".

Keppra was discovered and developed in UCB's research laboratories. UCB, with headquarters in Brussels (Belgium), is a pharmaceutical and chemical company which operates on a global scale. It is committed to pharmaceuticals, as well as to technically innovative products in surface specialities for flexible films and coating resins. It employs 10,000 people around the world. The pharmaceutical research of UCB includes the following fields : respiratory, including allergy and asthma, and neurology. UCB Pharma's principle products include Zyrtec®, Xyzal® (anti-allergic), KEPPRA® (antiepileptic), Nootropil® (cerebral function regulator) and Atarax® (tranquilliser).

* Keppra is a registered trademark of the UCB Group


References:
1. Ben Menachem et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Research 2003, 53 (1-2): 57-64
2. WHO Factsheet number 165: Epilepsy: Etiology, Epidemiology and Prognosis. http://www.who.int/inf-fs/en/fact165.html


SOURCE: Ketchum London

E-Mail this DGNews to a colleague

To print, use this version